Boosting local manufacturing: India plans incentives for diabetes, obesity drug makers in 2026
Bengaluru: India is set to provide incentives aimed at boosting domestic production of GLP-1 drugs, which are utilized to manage diabetes and obesity, according to a top government official.
GLP-1 drugs, initially sanctioned for diabetes treatment, are increasingly employed to combat obesity by delaying digestion, thereby extending the feeling of fullness among patients.
Danish drugmaker Novo Nordisk's patent on semaglutide - a GLP-1 agonist and the key ingredient in its wildly popular obesity drug Wegovy and diabetes drug Ozempic - is set to expire in India in 2026, industry experts say.
"The (Indian) companies (planning) manufacturing GLP-1 drugs have applied for the government's production-linked incentive (PLI) scheme," Arunish Chawla, Secretary of Department of Pharmaceuticals, told Reuters.
"Once they start manufacturing in 2026 after patent expiries, we will give them the incentive," said Chawla, without disclosing the names of these companies.
Drugmakers across the globe are looking to grab a slice of the weight-loss drugs market, which is estimated to reach at least $100 billion by the end of the decade.
India has high obesity rates, especially among women, and has the world's second-highest number of people with type 2 diabetes. Around 11% of Indian adults will be obese by 2035, according to the World Obesity Federation Atlas.
Domestic drugmakers Biocon, Sun Pharma, Cipla, Dr Reddy's and Lupin are all part of this club. They were not immediately available for comment on Friday.
India has offered incentives since 2020 to spur local manufacturing of everything from electronic products to drones, but has been successful only in a handful of them.
The drugmakers that will be considered for the upcoming incentive scheme have labeled their GLP-1 drugs use case as 'anti-diabetic' in their application, Chawla said.
"Their usage for obesity will depend on necessary approvals at that time from the drug regulator."
Read also: Biocon quest for partner in China to test generic versions of Novo Nordisk Wegovy, Ozempic
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.